Squalenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemia-bearing rats: Study of mechanisms

Anti-Cancer Drugs

Volumn 19, Issue 10, 2008, Pages 999-1006

  Reddy, Lakkireddy Harivardhan ^a   Ferreira, Humberto ^a   Dubernet, Catherine ^a   Mouelhi, Sinda Lepetre ^a   Desmaele, Didier ^a   Rousseau, Bernard ^b   Couvreur, Patrick ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b DIF   (France)

Author keywords

Biodistribution; Nanomedicine; Oral delivery; RNK 16 large granular lymphocytic leukemia; Squalenoyl gemcitabine

Indexed keywords

CYTIDINE DEAMINASE; GEMCITABINE; GEMCITABINE H 3; NUCLEOSIDE ANALOG; NUCLEOSIDE TRANSPORTER; SQUALENE; SQUALENOYLGEMCITABINE; SQUALENOYLGEMCITABINE H 3; UNCLASSIFIED DRUG; URACIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHOLESTEROL SYNTHESIS; CYTOTOXICITY; DEAMINATION; DRUG DOSAGE FORM COMPARISON; DRUG MECHANISM; FISCHER 344 RAT; IN VITRO STUDY; LARGE GRANULAR LYMPHOCYTE; LYMPHATIC LEUKEMIA; NANOMEDICINE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DEOXYCYTIDINE; LEUKEMIA, EXPERIMENTAL; NANOMEDICINE; RATS; RATS, INBRED F344; SQUALENE;

EID: 54249120139     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283126585     Document Type: Article

References (23)

1. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995; 13:2731-2736.
2. Pollera CF, Ceribelli A, Crecco M, Calabresi F. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 1994; 5:182-184.
3. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86:1530-1533.
4. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH. Single agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1994; 12:1821-1826.
5. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, et al. Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of pancreas. Invest New Drugs 1994; 12:29-34.
6. Catimel G, Vermorken JB, Clavel M, de Mulder P, Judson I, Sessa C, et al. A phase II study of gemcitabine (LY188011) in patients with advanced squamous carcinoma of the head and neck. Ann Oncol 1994; 5:543-547.
7. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JS, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998; 58:4349-4357.
8. Gourdeau H, Clarke ML, Ouellet F, Mowles D, Selner M, Richard A, et al. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. Cancer Res 2001; 61:7217-7224.
9. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 3:491-498.
10. Reid JM, Qu W, Safgren SL, Ames MM, Krailo MD, Seibel NL, et al. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors. J Clin Oncol 2004; 22:2445-2451.
11. Couvreur P, Stella B, Cattel L, Rocco F, Renoir J-M, Rosilio V. Nanoparticles of gemcitabine. French Patent 2006; WO/2006/090029.
12. Couvreur P, Stella B, Reddy LH, Hillaireau H, Dubernet C, Desmaële D, et al. Squalenoyl nanomedicines as potential therapeutics. Nano Lett 2006; 6:2544-2548.
13. Reddy LH, Dubernet C, Lepêtre-Mouelhi S, Desmaële D, Couvreur P. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types. J Control Release 2007; 124:20-27.
14. Couvreur P, Reddy LH, Mangenot S, Poupaert JH, Desmaële D, Lepetre-Mouelhi S, et al. Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue. Small 2008; 4:247-253.
15. Reddy LH, Marque PE, Dubernet C, Lepêtre-Mouelhi S, Desmaële D, Couvreur P. Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine. J Pharmacol Exp Ther 2008; 325:484-490.
16. Reddy LH, Khoury H, Paci A, Deroussent A, Ferreira H, Dubernet C, et al. Squalenoylation favourably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice. Drug Metab Dispos 2008; 36:1570-1577.
17. Kelly GS. Squalene and its potential clinical uses. Alt Med Rev 1999; 4:29-36.
18. Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci 2004; 95:753-757.
19. Hyde RJ, Cass CE, Young JD, Baldwin SA. The ENT family of eukaryote nucleoside and nucleobase transporters: recent advances in the investigation of structure/function relationships and the identification of novel isoforms. Mol Membrane Biol 2001; 18:53-63.
20. Shamseddine AI, Khalifeh MJ, Mourad FH, Chehal AA, Al-Kutoubi A, Abbas J, et al. Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients. Clin Pharmacokinet 2005; 44:957-967.
21. Roosterman D, Roth A, Kreienkamp HJ, Richter D, Meyerhof W. Distinct agonist-mediated endocytosis of cloned rat somatostatin receptor expressed in insulinoma cells. J Neuroendocrinol 1997; 9:741-751.
22. Veltkamp SA, Pluim D, van Tellingen O, Beijnen JH, Schellens JH. Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice. Drug Metab Dispos 2008; 36:1606-1615.
23. Veltkamp SA, Jansen RS, Callies S, Pluim D, Visseren-Grul CM, Rosing H, et al. Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice. Clin Cancer Res 2008; 14:3477-3486.